Hypolipidemia: Clinical Implications and Management

Definition and Classification

Hypolipidemia refers to abnormally low levels of lipids in the blood, which can be primary (genetic) or secondary, with distinct clinical implications for morbidity and mortality, according to the European Heart Journal 1

Individuals with PCSK9 loss-of-function mutations have LDL-C levels as low as 14 mg/dL and are associated with lower rates of cardiovascular events, as reported by the European Heart Journal 1
Carriers of PCSK9 loss-of-function mutations are generally healthy with no significant comorbidities, according to the European Heart Journal 1, 2
Abetalipoproteinemia is characterized by undetectable LDL-C and is associated with deficiency of fat-soluble vitamins, leading to severe neurological manifestations, as noted in the European Heart Journal 1
Smith-Lemli-Opitz Syndrome is caused by deficiency of 7-dehydrocholesterol reductase enzyme, with LDL-C levels as low as 20 mg/dL, and is associated with growth restriction, intellectual disability, and cardiac defects, as reported by the European Heart Journal 1, 3

Individuals with genetic forms of very low LDL-C demonstrate lower rates of cardiovascular events, with no observed plateau in cardiovascular benefit even at LDL-C levels as low as 10 mg/dL, according to the European Heart Journal 1, 3, 4
Neurological symptoms in hypolipidemic disorders are typically related to vitamin deficiencies rather than low lipid levels per se, as noted in the European Heart Journal 1
High-dose vitamin E supplementation can halt further neurological degeneration in conditions like abetalipoproteinemia, as reported by the European Heart Journal 1

Accurate measurement of very low LDL-C levels may require specialized methods beyond the standard Friedewald equation, such as the Martin/Hopkins method, which provides improved accuracy for measuring low LDL-C levels, as noted in the European Heart Journal 2